The company has earlier communicated, at the completion of the statistical analysis for the phase 1 clinical data, that it was decided that the results should be published through an abstract. The abstract with several experts as co-authors, was submitted to the USA's largest conference in sexual medicine, organized by the Sexual Medicine Society North America. The abstract contains in-depth results on the safety profile of LIB-01 and the efficacy signal that was detected, a long-lasting effect that persisted for four weeks after a 3-day treatment.

The SMSNA has now selected Dicot Pharma's results to be presented as an oral presentation under the block "Innovation and Sexual Medicine" at the yearly congress in Arizona in October 2024. The speaker is Dr. Harin Padma-Nathan, former professor of urology at the University of Southern California and responsible study physician in Viagra and Cialis trials. Charlotta Gauffin, Dicot Pharma's CSO, will also participate as a representative of the company. The abstract will also be published in the scientific journal The Journal of Sexual Medicine, which is published on behalf of the International Society for Sexual Medicine.

"I would say that our clinical results are breaking news in the field that deserves the right opportunity to be presented. No new, innovative drug has reached the market since Viagra, so there is a great interest in our candidate," says Elin Trampe, Dicot Pharma's CEO.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Spotlight Stock Market and has approximately 6,100 shareholders. For more information, please visit www.dicotpharma.com.